Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026

Reuters

Sep 11, 2025

Enlivex <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced the topline results of its Phase IIa trial for Allocetra™ in knee osteoarthritis (KOA). The trial demonstrated statistically significant and clinically meaningful improvements in pain and function among primary osteoarthritis patients. The company anticipates a six-month data readout from the ongoing Phase IIa trial in November 2025. Additionally, Enlivex plans to initiate a Phase IIb trial in the second quarter of 2026, with regulatory approval of the protocol expected in the first half of the same year. The company is actively pursuing potential partnerships and funding opportunities based on these positive trial results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527377-en) on September 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566998288"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566998288\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566998288?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566998288","market":"nz","top_or_hot":-1,"title":"Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a>, a clinical-stage macrophage reprogramming immunotherapy company, has announced the topline results of its Phase IIa trial for Allocetra™ in knee osteoarthritis (KOA). The trial demonstrated statistically significant and clinically meaningful improvements in pain and function among primary osteoarthritis patients. The company anticipates a six-month data readout from the ongoing Phase IIa trial in November 2025. Additionally, Enlivex plans to initiate a Phase IIb trial in the second quarter of 2026, with regulatory approval of the protocol expected in the first half of the same year. The company is actively pursuing potential partnerships and funding opportunities based on these positive trial results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527377-en) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnlivex Therapeutics Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-11 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a>, a clinical-stage macrophage reprogramming immunotherapy company, has announced the topline results of its Phase IIa trial for Allocetra™ in knee osteoarthritis (KOA). The trial demonstrated statistically significant and clinically meaningful improvements in pain and function among primary osteoarthritis patients. The company anticipates a six-month data readout from the ongoing Phase IIa trial in November 2025. Additionally, Enlivex plans to initiate a Phase IIb trial in the second quarter of 2026, with regulatory approval of the protocol expected in the first half of the same year. The company is actively pursuing potential partnerships and funding opportunities based on these positive trial results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527377-en) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL2jBvH0:1","article_id":"2566998288","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566998288","pubTimestamp":1757592038,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra in Knee Osteoarthritis; Plans Phase IIb Trial in 2026. Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced the topline results of its Phase IIa trial for Allocetra in knee osteoarthritis . The trial demonstrated statistically significant and clinically meaningful improvements in pain and function among primary osteoarthritis patients. The company anticipates a six-month data readout from the ongoing Phase IIa trial in November 2025. Additionally, Enlivex plans to initiate a Phase IIb trial in the second quarter of 2026, with regulatory approval of the protocol expected in the first half of the same year. The company is actively pursuing potential partnerships and funding opportunities based on these positive trial results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ENLV":"Enlivex Therapeutics Ltd.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Enlivex Therapeutics宣布Allocetra的IIa期结果令人鼓舞™在膝骨关节炎中；计划2026年进行IIb期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENLV":0.9,"NDAQ":0.9},"content_text":"Enlivex Therapeutics Announces Promising Phase IIa Results for Allocetra™ in Knee Osteoarthritis; Plans Phase IIb Trial in 2026\n    \n\nEnlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced the topline results of its Phase IIa trial for Allocetra™ in knee osteoarthritis (KOA). The trial demonstrated statistically significant and clinically meaningful improvements in pain and function among primary osteoarthritis patients. The company anticipates a six-month data readout from the ongoing Phase IIa trial in November 2025. Additionally, Enlivex plans to initiate a Phase IIb trial in the second quarter of 2026, with regulatory approval of the protocol expected in the first half of the same year. The company is actively pursuing potential partnerships and funding opportunities based on these positive trial results.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527377-en) on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}